ADVERTISEMENT

Alembic Pharma Q3 Results Review - Efforts Underway To Sustain Margin Revival: Motilal Oswal

Alembic Pharma has guided for a 15-20% YoY reduction in R&D expenses in FY24 on account of portfolio optimisation.

<div class="paragraphs"><p>(Photo: PxHere)</p></div>
(Photo: PxHere)
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy. 
To continue reading this story
Subscribe to unlock & enjoy all Members-only benefits

Choose a plan

Renews automatically. Cancel anytime.
Still Not convinced ? Know More